Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States
- PMID: 30294518
- PMCID: PMC6168203
- DOI: 10.1007/s11901-018-0394-x
Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States
Abstract
Purpose of review: Direct-acting antiviral regimens for chronic hepatitis C virus (HCV) became available in 2014, and these highly curative therapies have the potential to reduce HCV-associated morbidity and mortality, decrease transmission, and eliminate HCV infection as a public health problem. This review summarizes the recommendations by the National Academies of Sciences, Engineering, and Medicine for a US strategy for HCV elimination.
Recent findings: To achieve proposed targets of reducing HCV incidence by 90% and decreasing HCV-related mortality by 60% by 2030, there is a critical need to improve HCV diagnosis and linkage to care; reduce HCV-related disease by antiviral treatment scale-up; reduce HCV incidence; and strengthen HCV surveillance to determine achievement of HCV elimination targets over time.
Summary: While HCV elimination is feasible, success of this national effort will require ongoing collaboration and critical resource investment by key stakeholders, including medical and public health communities, legislators, community organizers, and patient advocates.
Keywords: US public health threats; elimination; hepatitis C.
Conflict of interest statement
Conflict of Interest Charitha Gowda declares no conflicts of interest.
Figures
Similar articles
-
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C.Adv Ther. 2021 Jan;38(1):423-440. doi: 10.1007/s12325-020-01535-3. Epub 2020 Nov 3. Adv Ther. 2021. PMID: 33145648 Free PMC article.
-
Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.J Hepatol. 2018 May;68(5):932-939. doi: 10.1016/j.jhep.2017.12.013. Epub 2017 Dec 21. J Hepatol. 2018. PMID: 29274408
-
Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.Int J Drug Policy. 2019 Oct;72:1-10. doi: 10.1016/j.drugpo.2019.07.016. Epub 2019 Jul 23. Int J Drug Policy. 2019. PMID: 31345644
-
Hepatitis C elimination: a Public Health Perspective.Curr Treat Options Gastroenterol. 2019 Sep;17(3):367-377. doi: 10.1007/s11938-019-00240-7. Curr Treat Options Gastroenterol. 2019. PMID: 31321673 Review.
-
Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy.Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101564. doi: 10.1016/j.clinre.2020.11.001. Epub 2021 Mar 16. Clin Res Hepatol Gastroenterol. 2021. PMID: 33740477 Review.
Cited by
-
Implementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut.Public Health Rep. 2024 Mar-Apr;139(2):208-217. doi: 10.1177/00333549231172173. Epub 2023 May 26. Public Health Rep. 2024. PMID: 37232422 Free PMC article.
-
Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017.Am J Prev Med. 2021 Feb;60(2):285-293. doi: 10.1016/j.amepre.2020.08.031. Epub 2020 Nov 19. Am J Prev Med. 2021. PMID: 33221144 Free PMC article.
-
Estimated Number of People Who Inject Drugs in the United States.Clin Infect Dis. 2023 Jan 6;76(1):96-102. doi: 10.1093/cid/ciac543. Clin Infect Dis. 2023. PMID: 35791261 Free PMC article.
-
Translation and validation study of the Polish version of the Brief Hepatitis C Knowledge Scale.PLoS One. 2020 Jul 9;15(7):e0235764. doi: 10.1371/journal.pone.0235764. eCollection 2020. PLoS One. 2020. PMID: 32645071 Free PMC article.
-
Association between Direct-Acting Agents Adherence and Health-Related Quality of Life of Patients with Hepatitis C.Curr Health Sci J. 2023 Jul-Sep;49(3):312-318. doi: 10.12865/CHSJ.49.03.02. Epub 2023 Sep 30. Curr Health Sci J. 2023. PMID: 38314219 Free PMC article.
References
-
- Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146(5):1176–92. doi: 10.1053/j.gastro.2014.03.003. Important initial review summarizing the development of direct-acting antiviral agents and interferon-sparing treatment strategies for chronic HCV infection. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials